Targeting The Leading Cause Of Death In Friedreich’s Ataxia With A Gene Therapy RARECast podcast

Artwork

Health Industry Business Health Care Rare Disease RARECast Health and Well-Being

Indhold leveret af RARECast. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af RARECast eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

RARECast « »
Targeting the Leading Cause of Death in Friedreich’s Ataxia with a Gene Therapy

4M ago 24:39

Del

MP3•Episode hjem

Indhold leveret af RARECast. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af RARECast eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Friedreich’s ataxia is a rare, genetic, degenerative disorder that affects multiple systems in the body. As the disease progresses, patients typically experience various heart conditions. Hypertrophic cardiomyopathy, fibrosis, heart failure, and arrhythmias are the cause of death in approximately two-thirds of Friedreich’s ataxia patients. Lexeo Therapeutics is developing a gene therapy to treat FA cardiomyopathy. We spoke to R. Nolan Townsend, CEO of Lexeo Therapeutics, about Friedreich’s ataxia, the company’s gene therapy in development, and its pursuit of gene therapies for both rare and common diseases.

… continue reading

491 episoder

#Health Industry #Business #Health Care #Rare Disease #RARECast #Health and Well-Being

Artwork

Targeting the Leading Cause of Death in Friedreich’s Ataxia with a Gene Therapy

28 subscribers

published 4M ago

Del

MP3•Episode hjem

Indhold leveret af RARECast. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af RARECast eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Friedreich’s ataxia is a rare, genetic, degenerative disorder that affects multiple systems in the body. As the disease progresses, patients typically experience various heart conditions. Hypertrophic cardiomyopathy, fibrosis, heart failure, and arrhythmias are the cause of death in approximately two-thirds of Friedreich’s ataxia patients. Lexeo Therapeutics is developing a gene therapy to treat FA cardiomyopathy. We spoke to R. Nolan Townsend, CEO of Lexeo Therapeutics, about Friedreich’s ataxia, the company’s gene therapy in development, and its pursuit of gene therapies for both rare and common diseases.

… continue reading

491 episoder

#Health Industry #Business #Health Care #Rare Disease #RARECast #Health and Well-Being

All episodes

×

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

Lyt til 500+ emner